8-K: Enanta's Zelicapavir Shows Positive RSV Phase 2b Results

Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for respiratory syncytial virus (RSV) in high-risk adults, demonstrating clinically meaningful symptom and virology improvements.

Summary

• Positive topline data from the Phase 2b RSVHR study of zelicapavir (formerly EDP-938) for the treatment of respiratory syncytial virus (RSV) in high-risk non-hospitalized adults was announced.
• The study included elderly patients and/or those with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or asthma.
• Zelicapavir demonstrated a favorable safety profile over the 5-day dosing period and 28 days of follow-up, with adverse events (AEs) being similar between zelicapavir and placebo, and no AEs leading to treatment discontinuation.
• A clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for the HR3 population (CHF, COPD, or age >75).
• Zelicapavir also showed an improvement in time to complete resolution on the 29-parameter total RiiQ symptom scale of 3.6 days for the efficacy population and 7.2 days for the HR3 population.
• A 3.0-day faster time to complete resolution of lower respiratory tract disease (LRTD) symptoms was observed in the HR3 population.
• The study met a key secondary endpoint with zelicapavir treatment resulting in a statistically significant 2-day faster improvement in a Patient Global Impression of Severity (PGI-S) score compared to placebo in both the efficacy (p=0.0446) and HR3 (p=0.0465) populations.
• A lower hospitalization rate was observed for patients treated with zelicapavir (1.7%) compared to placebo (5.0%), with investigators judging none (0%) of zelicapavir hospitalizations and all (5.0%) of placebo hospitalizations to be RSV-related.
• Key secondary virology endpoints were met, showing a robust antiviral effect with a statistically significantly greater proportion of zelicapavir patients having an undetectable viral load at the end of treatment (23.5% vs 10.0% in efficacy, p=0.0198; 23.9% vs 10.0% in HR3, p=0.0292).
• Treatment with zelicapavir resulted in a 4or 5-day faster median time to undetectable viral load and a 0.6 or 0.7 log decline in viral load at the end of treatment compared to placebo for the efficacy and HR3 populations, respectively.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive topline results from a Phase 2b study for a drug targeting a significant unmet medical need. While the primary endpoint was not met, several key secondary endpoints, including clinically meaningful symptom resolution, reduced hospitalizations, and robust antiviral effects, were achieved. This suggests strong potential for future development and commercialization.

Positives

• Zelicapavir demonstrated a favorable safety profile, with adverse events similar to placebo and no treatment discontinuations.
• Clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms (2.2 days faster for efficacy population, 6.7 days faster for HR3 population).
• Improvement in total RiiQ (29 parameters) symptom scale (3.6 days faster for efficacy population, 7.2 days faster for HR3 population).
• 3.0-day faster time to complete resolution of lower respiratory tract disease (LRTD) symptoms in the HR3 population.
• Statistically significant 2-day faster improvement in Patient Global Impression of Severity (PGI-S) score (p=0.0446 for efficacy, p=0.0465 for HR3).
• Lower hospitalization rate for zelicapavir (1.7%) compared to placebo (5.0%), with 0% of zelicapavir hospitalizations judged RSV-related by investigators.
• Robust antiviral effect with statistically significantly greater proportion of zelicapavir patients having an undetectable viral load at the end of treatment (23.5% vs 10.0% in efficacy, 23.9% vs 10.0% in HR3).
• 4to 5-day faster median time to undetectable viral load and a 0.6 or 0.7 log decline in viral load at the end of treatment.
• Zelicapavir received Fast Track designation from the U.S. Food and Drug Administration (FDA).
• Identified multiple potential registrational endpoints for a Phase 3 trial.

Negatives

• No effect was observed on the primary endpoint of time to resolution of the LRTD subset of four symptoms to mild in the efficacy population.

Risks

• Development risks associated with early-stage discovery efforts in disease areas like RSV.
• Potential impact of development, regulatory, and marketing efforts by competitors for RSV treatments.
• Limited clinical development experience of the company.
• Challenges in attracting and retaining senior management and key scientific personnel.
• Need to obtain and maintain patent protection for product candidates and avoid potential infringement of intellectual property rights of others.
• Other risk factors detailed in the company's most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024, and other periodic SEC reports.

Future Outlook

Management is highly encouraged by the Phase 2b results, believing they validate zelicapavir's mechanism of action and reinforce its potential as a broadly effective, first-in-class RSV treatment. The data provides strong rationale for further clinical advancement, and multiple potential registrational endpoints for a Phase 3 trial have been identified.

Management Comments

• "We are highly encouraged by these results from our Phase 2b trial of zelicapavir in high-risk adults infected with RSV. This represents the first time an RSV antiviral treatment has demonstrated a clinically meaningful benefit in these high-risk adult outpatients." Scott T. Rottinghaus, M.D., Chief Medical Officer of Enanta Pharmaceuticals.
• "These data demonstrate the potential for zelicapavir to reduce the duration of RSV symptoms in high-risk adults who face an increased risk of hospitalization or death from this virus." Scott T. Rottinghaus, M.D., Chief Medical Officer of Enanta Pharmaceuticals.
• "We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial." Scott T. Rottinghaus, M.D., Chief Medical Officer of Enanta Pharmaceuticals.
• "The RSV symptom benefit observed in this study is compelling and could significantly improve outcomes for high-risk adults." Mohamed Fayed, M.D., UCSF School of Medicine Regional Campus at Fresno, a Principal Investigator in the study.

Industry Context

Respiratory Syncytial Virus (RSV) is a common respiratory virus that poses a significantly increased risk of severe illness, hospitalization, or death for older adults and individuals with underlying health conditions such as COPD, asthma, or chronic heart failure. Currently, there are no safe and effective antiviral RSV treatments available, making zelicapavir's potential to reduce symptom duration and hospitalization rates a significant development in addressing this unmet medical need.

Comparison to Industry Standards

• This represents the first time an RSV antiviral treatment has demonstrated a clinically meaningful benefit in high-risk adult outpatients, suggesting a potential first-in-class therapy for this specific patient population and outcome.
• Zelicapavir is differentiated from RSV fusion inhibitors as an N-protein inhibitor, targeting the virus replication machinery and demonstrating a high barrier to resistance in vitro.
• Preclinical studies showed zelicapavir maintained antiviral potency across all clinical isolates tested and was active against viral variants resistant to other mechanisms.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, potentially increasing company valuation and future revenue streams.
• Patients (High-Risk Adults with RSV): Potential for a new, effective treatment to reduce symptom duration, severity, and hospitalization rates, improving quality of life and reducing mortality risk.
• Healthcare Providers: A new therapeutic option for managing RSV in vulnerable populations.

Next Steps

• Inform the design of a Phase 3 trial, including populations and endpoints.
• Present full data from the study at a future medical conference or in a peer-reviewed publication.
• Host a conference call and webcast on September 29, 2025, at 8:30 a.m. ET to discuss the results.

Key Dates

Recommendation

The positive topline results from the Phase 2b study of zelicapavir for RSV in high-risk adults are highly encouraging. Despite not meeting the primary endpoint, the drug demonstrated clinically meaningful improvements across multiple key secondary endpoints, including significant reductions in symptom duration, hospitalization rates, and viral load. The favorable safety profile and Fast Track designation further de-risk the development pathway. Given the substantial unmet medical need for RSV treatments in this vulnerable population and the potential for zelicapavir to be a first-in-class therapy, these results provide a strong rationale for a 'strong buy' recommendation, anticipating significant upside potential as the drug progresses to Phase 3 and potential commercialization.

Keywords

Enanta Pharmaceuticals, Zelicapavir, RSV, Respiratory Syncytial Virus, Phase 2b, Clinical Trial, Antiviral, N-protein inhibitor, High-Risk Adults, Biotechnology, Drug Development, FDA Fast Track